NAS10026,990+1.35%S&P7,377+0.31%GOLD$4,075−0.94%BTC$75,677−0.09%VIX25.64−9.01%latest tape · as of 20:08 UTC
The Screen · Healthcare · Drug Manufacturers - Specialty & Generic
Takeda Pharmaceutical Co ADR
TAK · the NYSE · USD · Market cap $66.3B
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 3.52, read 2026-11-05
Ethical passes the values gate
Price21.02 USD
Fair value16.82
Ethical score70.0/100
Value readOvervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup17.86+17.7% to today ✓Accumulation gives way to Markup first Markup read since September
2026-10-02Read Accumulation17.86+17.7% to today ✓Markup gives way to Accumulation while volume is distributing
2026-08-14Read Markup17.02+23.5% to today ✓Distribution gives way to Markup after a 7% rise in 6 weeks
2026-07-02Read Distribution15.91+32.1% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Takeda Pharmaceutical Co ADR holds its Markup at $21.02. Consolidating, no directional conviction, held for 735 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 735 days
Price at the screen
$21.02
Valuation
296.43 trailing · 39.15 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.08
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
31.47%
Below 33%
Interest-bearing debt is just 31.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
2.84%
Below 33%
Cash held in interest-bearing accounts and securities is 2.8% of assets, under the one-third limit.
Pass
Receivables
10.14%
Below 49%
Money owed to the company is 10.1% of assets, under the 49% limit.
Pass
Revenue purity
0.37%
Below 5%
Only 0.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Takeda Pharmaceutical Co clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 31%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TAK's ethical verdict changes
Today TAK passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 6 Nov 2026: it trades above our $16.82 fair value estimate, narrow competitive moat, 6.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. The price runs 25.0% above the base estimate.
Where our models see it going: fair-value estimate $16.82, with a range of $16.82 to $19.34, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Big Pharma Name Trading Well Above Value
Picture a Japanese drugmaker selling treatments for gut disorders and rare diseases. Patients still need the medicines, yet the shares sit at seventeen dollars while our fair value sits at thirteen. That leaves a negative margin of safety and an opportunity rating of none.
Revenue edges up only four percent and both profit margin and return on equity sit in negative territory. A narrow moat and a thirty-two times forward earnings multiple on such thin growth do not justify the premium. The ethical screen clears, yet the numbers still fail our test.
Three analysts call it a strong buy with a twenty-one dollar target, but peak earnings and a stretched multiple often signal the opposite of value. Currency moves and pipeline setbacks add further uncertainty. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Japan and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TAK trades on the NYSE (the company is based in Japan). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markup$20.91+6.6%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (3 analysts) rates it strong buy, with a mean price target of $21. Since the last review it entered the Titan Ethical 500.
2026-10-25Markup$19.61+0.8%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (3 analysts) rates it strong buy, with a mean price target of $21.
2026-10-18Markup$19.45+8.9%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (3 analysts) rates it strong buy, with a mean price target of $21.
2026-10-11Markup · changed$17.86+0.0%Entry 7
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (3 analysts) rates it strong buy, with a mean price target of $21.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (3 analysts) rates it strong buy, with a mean price target of $21.
2026-09-14Markup$18.26+7.3%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (3 analysts) rates it strong buy, with a mean price target of $21.
2026-08-14Markup · changed$17.02+7.0%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (3 analysts) rates it strong buy, with a mean price target of $21.
2026-07-18Distribution$15.91+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (3 analysts) rates it strong buy, with a mean price target of $21.
2026-07-03Distribution$15.91+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Distribution$15.91Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
